Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~* Phase 1:~* Male or female, from 18 years to 49 years of age inclusive~* Phase 2:~* Male or female ≥50 years of age Phase 1 and Phase 2~* Males: refrain from donating sperm, remain abstinent during study or agree to use condom~* Females: Not pregnant. If a woman of childbearing potential, agree to use contraception or remain abstinent~Exclusion Criteria~* History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years of screening~* Known hypersensitivity to any component of the pPCV, or any diphtheria toxoid-containing vaccine~* Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease~* Coagulation disorder contraindicating IM vaccination~* Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F \[≥38.0°C\] or axillary or temporal temperature ≥99.4°F \[≥37.4°C\]) or received antibiotic therapy for any acute illness occurring within 72 hours of screening~* Known malignancy that is progressing or has required active treatment within 3 years.(Note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ \[eg, breast carcinoma, cervical cancer in situ\] that have undergone potentially curative therapy are not excluded)~* Pregnant~* Received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study, outside of the protocol.~* Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease~* Received a blood transfusion or blood products, including immunoglobulin, 6 months before study vaccination or is scheduled to receive a blood transfusion or blood product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Phase 1: V116 0.5 mL (Type: EXPERIMENTAL): Participants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1
- Phase 1: V116 1.0 mL (Type: EXPERIMENTAL): Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1
- Phase 1: Pneumovax™23 (Type: ACTIVE_COMPARATOR): Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1
- Phase 2: V116 (Type: EXPERIMENTAL): Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2
- Phase 2: Pneumovax™23 (Type: ACTIVE_COMPARATOR): Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete